Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

Zausinger, S; Lumenta, DB; Pruneau, D; Schmid-Elsaesser, R; Plesnila, N; Baethmann, A.
Effects of LF 16-0687 Ms, a bradykinin B(2) receptor antagonist, on brain edema formation and tissue damage in a rat model of temporary focal cerebral ischemia.
Brain Res. 2002; 950(1-2):268-278
Web of Science PubMed FullText FullText_MUG

 

Autor/innen der Med Uni Graz:
Lumenta David Benjamin
Altmetrics:

Dimensions Citations:

Plum Analytics:
Abstract:
Bradykinin, an endogenous nonapeptide produced by activation of the kallikrein-kinin system, promotes neuronal tissue damage as well as disturbances in blood-brain barrier function through activation of B(2) receptors. LF 16-0687 Ms, a non-peptide competitive bradykinin B(2) receptor antagonist, was recently found to decrease brain swelling in various models of traumatic brain injury. We have investigated the influence of LF 16-0687 Ms on the edema formation, neurological outcome, and infarct size in temporary focal cerebral ischemia in rats. Sprague-Dawley rats were subjected to MCA occlusion for 90 min by an intraluminal filament. Local CBF was bilaterally recorded by laser Doppler flowmetry. Study I: animals were assigned to one of three treatment arms (n=11 each): (a) vehicle, (b) LF 16-0687 Ms (12.0 mg/kg per day), or (c) LF 16-0687 Ms (36.0 mg/kg per day) given repetitively s.c. over 3 days. The neurological recovery was examined daily. The infarct volume was assessed histologically 7 days after ischemia. Study II: brain swelling and bilateral hemispheric water content were determined at 48 h post ischemia in eight rats, subjected to the low dose regimen as described above, and in eight vehicle-treated control animals. All treated animals showed tendency to exhibit improved neurological recovery throughout the observation period as compared to the vehicle-treated controls, while this improvement was only significant within the low dose group from postischemic days 3 to 4. Low dose LF 16-0687 Ms significantly attenuated the total and cortical infarct volume by 50 and 80%, respectively. Furthermore, postischemic swelling (-62%) and increase in water content of the infarcted brain hemisphere (-60.5%) was significantly inhibited. The present findings provide strong evidence for an involvement of bradykinin-mediated secondary brain damage following from focal cerebral ischemia. Accordingly, specific inhibition of bradykinin B(2) receptors by LF 16-0687 Ms attenuated postischemic brain swelling, improved the functional neurological recovery, and limited ischemic tissue damage, raising its potential for clinical evaluation in patients with acute stroke.
Find related publications in this database (using NLM MeSH Indexing)
Animals -
Brain - drug effects Brain - pathology
Brain Edema - drug therapy Brain Edema - pathology Brain Edema - physiopathology
Brain Ischemia - drug therapy Brain Ischemia - pathology Brain Ischemia - physiopathology
Disease Models, Animal -
Male -
Quinolines - pharmacology Quinolines - therapeutic use
Rats -
Rats, Sprague-Dawley -
Receptor, Bradykinin B2 -
Receptors, Bradykinin - antagonists and inhibitors Receptors, Bradykinin - physiology

Find related publications in this database (Keywords)
cerebral ischemia, focal
bradykinin
bradykinin B-2
receptor antagonization
laser-Doppler flowmetry
neuroprotection
brain edema
© Meduni Graz Impressum